COYA
Coya Therapeutics, Inc
Coya Therapeutics, Inc historical holders
total: 1
Greenlight Capital Coya Therapeutics, Inc transactions over time
- Total transactions:
- 7
- New positions:
- 1
- Added:
- 6
- Held since:
- 2022 Q4
- Held for:
- 14 quarters
- Latest activity:
- 2026 Q1
David Einhorn has been an institutional investor in Coya Therapeutics, Inc (COYA) since 2022 Q4. According to 2026 Q1 report, David Einhorn holds 2,335,540 shares with a market value of roughly $9.20M representing 0.29% of their equity portfolio. The fund/company first acquired COYA in 2022 Q4, initially purchasing 392,444 shares. Since the initial investment, Greenlight Capital has made 6 more transactions in this position.
Does David Einhorn still hold COYA?
Yes, David Einhorn continues to hold Coya Therapeutics, Inc (COYA). According to their 2026 Q1 report, they maintain a position of 2,335,540 shares valued at approximately $9.20M, representing 0.29% of their equity portfolio.
When did David Einhorn first invest in COYA?
David Einhorn first invested in Coya Therapeutics, Inc (COYA) in 2022 Q4 at the reported quarter-end price of $4.74 per share, acquiring 392,444 shares in their initial purchase.
What is David Einhorn's average cost basis for COYA?
Based on historical transaction data, David Einhorn's estimated cost basis for Coya Therapeutics, Inc (COYA) is approximately $5.86 per share. This represents their average reported price* across all buy transactions.
Estimated cost basis*
- Weighted AVG buy price:
- $5.86
COYA transactions history by Greenlight Capital
7 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2026 Q1
|
0.29%
|
2,335,540
|
$3.94
|
$9,202,027
|
+15.28% (+309,600)
|
+0.04%
|
|
2025 Q4
|
0.41%
|
2,025,940
|
$5.80
|
$11,750,452
|
+23.05% (+379,500)
|
+0.08%
|
|
2024 Q4
|
0.49%
|
1,646,440
|
$5.73
|
$9,434,101
|
+29.23% (+372,414)
|
+0.11%
|
|
2023 Q4
|
0.46%
|
1,274,026
|
$7.41
|
$9,440,533
|
+172.19% (+805,959)
|
+0.29%
|
|
2023 Q3
|
0.10%
|
468,067
|
$3.84
|
$1,797,377
|
+19.21% (+75,420)
|
+0.02%
|
|
2023 Q1
|
0.08%
|
392,647
|
$3.97
|
$1,560,183
|
+0.05% (+203)
|
+0%
|
|
2022 Q4
|
0.13%
|
392,444
|
$4.74
|
$1,859,439
|
new
|
+0.13%
|
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.